XOMA to Present at Upcoming Investor Conferences
December 21, 2021 07:30 ET
|
XOMA Corporation
EMERYVILLE, Calif., Dec. 21, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator playing a distinctive role in helping companies achieve their goal of...
XOMA Announces Evolution of Company Leadership and Succession Planning
December 16, 2021 07:30 ET
|
XOMA Corporation
Chief Executive Officer Jim Neal appointed as Chairman; Former Chairman W. Denman Van Ness to remain Lead Independent Director Company is launching Chief Executive Officer search; Jim...
XOMA Earns $35 Million Milestone Payment as Anti-TGFβ Antibody Enters Phase 3 Clinical Study in Metastatic Pancreatic Cancer
November 04, 2021 07:40 ET
|
XOMA Corporation
EMERYVILLE, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) announced today NIS793, an anti-TGFβ monoclonal antibody licensed from the Company, has advanced to the Phase 3...
XOMA Reports Third Quarter 2021 Financial Results and Highlights Recent Operational Events
November 04, 2021 07:30 ET
|
XOMA Corporation
Added eight assets to its portfolio of potential milestone and royalty assets in 2021 NIS793 in combination with standard of care chemotherapy was granted Orphan Drug Designation for the treatment of...
XOMA to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference
September 22, 2021 07:30 ET
|
XOMA Corporation
EMERYVILLE, Calif., Sept. 22, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA)’s Chief Executive Officer, Jim Neal, will present at the 2021 Cantor Fitzgerald Virtual Global Healthcare...
XOMA Declares Quarterly Preferred Stock Dividends
September 20, 2021 07:30 ET
|
XOMA Corporation
EMERYVILLE, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to...
XOMA to Present at H.C. Wainwright 23rd Annual Global Investment Conference
September 13, 2021 07:30 ET
|
XOMA Corporation
EMERYVILLE, Calif., Sept. 13, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today its Chief Executive Officer, Jim Neal, will present at the H.C. Wainwright 23rd Annual Global...
XOMA Announces Heather L. Franklin Joins its Board of Directors
August 10, 2021 16:35 ET
|
XOMA Corporation
EMERYVILLE, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today Heather L. Franklin, President and Chief Executive Officer of Blaze Bioscience, Inc., has joined...
XOMA Reports Second Quarter 2021 Financial Results and Highlights Recent Operational Events
August 05, 2021 07:30 ET
|
XOMA Corporation
Added six assets to its portfolio of potential milestone and royalty assets in 2021 Company earned $0.5 million milestone as Janssen asset entered Phase 3 development NIS793 in combination with...
U.S. Food and Drug Administration has Granted Orphan Drug Designation to XOMA’s Licensed anti-TGFβ Asset NIS793
July 28, 2021 07:30 ET
|
XOMA Corporation
EMERYVILLE, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), announced today NIS793 in combination with standard of care chemotherapy has been granted Orphan Drug...